Cancer drug discovery: The wisdom of imprecision

Nature Medicine

Volumn 10, Issue 12, 2004, Pages 1298-1299

  Gudkov, Andrei V ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P53; PROTEIN P53 ACTIVATOR; REACTIVATION OF P53 AND INDUCTION OF TUMOR CELL APOPTOSIS PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SHORT SURVEY; TUMOR CELL;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; FURANS; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 11144327195     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1204-1298     Document Type: Short Survey

References (4)

1. Issaeva, N. et al. Nat. Med. 10, 1321-1328 (2004).
2. Fischer, P.M. & Lane, D.P. Trends Pharmacol. Sci. 25 343-346 (2004).
3. Vassilev, L.T. et al. Science 303, 844-848 (2004).
4. Bykov, V.J. et al. Nat. Med. 8, 282-288 (2002).